Jeff Arnold: Yes. Yes, I would say in the overall market is it’s competitive. But we are well diversified. So as you know, we work with large health plans and we work hard every day to drive value for Carelon and Elevance as one example, but other plans as well. We have several large employer clients, as you know, and we’ve invested kind of heavily in sales to kind of increase our RFPs. We’ve invested in government and we have some good success stories there with the state of Georgia and others. We have health systems, which we’re starting to do some really effective cross-selling in and turning health system clients into enterprise clients for their employees. We’ve started to add TPAs this quarter, which we see as a big growth area for us.
And so I think the diversification of Sharecare helps us a lot. So we can go-to-market with a Carelon or we can go direct through our sales force or we can cross-sell. And so it’s given us a lot of that best that, that help us in a competitive market.
David Larsen: Okay. Congrats on the good quarter. I’ll hop back in the queue. Thank you.
Jeff Arnold: Thank you.
Operator: The next question comes from Eric Percher of Nephron Research. Please go ahead.
Eric Percher: Thank you. To start on the enterprise side, good to hear about the live additions. Could you speak a little bit about development of the marketplace and maybe as we think about lives ex-Carelon, what are you’re seeing among the Blues targets for the year and whether it’s keeping pace with expectation?
Jeff Arnold: Well, I think on — on covered lives, it’s — we’re keeping pace with expectations, so selling through our partners like Carelon is meeting expectations. Our sales force delivering new logos is meeting expectations. A continued focus on the Blues plan and we’ve added a new Blues plan this year continues to be on mark. So all those things are progressing as plan. As the marketplace goes, we’re having success in upselling our digital therapeutics to our installed base. And we’re leading with our owned solutions, which give us higher margin and more revenue. And so we’re starting to see some good pull through in that area as well.
Jaffry Mohammed: Yes. Also our partnership with Carelon where we are jointly selling the market that you mentioned is tracking very well.
Eric Percher: Okay. So that seems to be an important factor. You mentioned your own offerings and you mentioned GLP-1s, which it seems to be the hot topic this earning season. Can you give us a little bit more on what you’ve done there with RealAge and what management looks like for you beyond that?
Jeff Arnold: Well, yes. We’ve done a lot of work in the GLP-1 space since we last talked of understanding on our clients of should this be a managed service or what’s the cost if it goes unmanaged. And then what are the unique assets that Sharecare has that it could marry with a GLP medication so that you could get sustained results. And so we already have our RealAge program that is then distributed to 13 million covered lives. And so people have their RealAge program and we already have a CDC approved weight loss program in Eat Right Now that came from our MindSciences acquisition. That’s all based on mindfulness and how to curb cravings. We have obviously Sharecare Plus and our advocates that can help with insurance companies. And so we’re packaging all that together and creating a B2B offering that we’re going to launch in January of next year to our enterprise clients.
Eric Percher: Interesting. And do you partner to the life sciences part of the market here as well?
